These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

663 related items for PubMed ID: 15086694

  • 1. Impact of selective cyclooxygenase-2 inhibitors on anti-ulcer medication and non-steroidal anti-inflammatory drug use in patients with rheumatic disease.
    Joshua FF, Oakley SP, Major GA.
    Intern Med J; 2004 Apr; 34(4):153-61. PubMed ID: 15086694
    [Abstract] [Full Text] [Related]

  • 2. Gastroprotective drugs in Australia: utilization patterns between 1997 and 2006 in relation to NSAID prescribing.
    Barozzi N, Tett SE.
    Clin Ther; 2009 Apr; 31(4):849-61. PubMed ID: 19446158
    [Abstract] [Full Text] [Related]

  • 3. Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy.
    Wolfe F, Anderson J, Burke TA, Arguelles LM, Pettitt D.
    J Rheumatol; 2002 Mar; 29(3):467-73. PubMed ID: 11908558
    [Abstract] [Full Text] [Related]

  • 4. National trends in cyclooxygenase-2 inhibitor use since market release: nonselective diffusion of a selectively cost-effective innovation.
    Dai C, Stafford RS, Alexander GC.
    Arch Intern Med; 2005 Jan 24; 165(2):171-7. PubMed ID: 15668363
    [Abstract] [Full Text] [Related]

  • 5. Impact of selective cyclooxygenase-2 inhibitors on anti-ulcer medication and non-steroidal anti-inflammatory drug use in patients with rheumatic disease.
    Fenn GC, Grobler M, Schaffer D.
    Intern Med J; 2004 Nov 24; 34(11):647-9; discussion 650. PubMed ID: 15546461
    [No Abstract] [Full Text] [Related]

  • 6. A Medicare database review found that physician preferences increasingly outweighed patient characteristics as determinants of first-time prescriptions for COX-2 inhibitors.
    Schneeweiss S, Glynn RJ, Avorn J, Solomon DH.
    J Clin Epidemiol; 2005 Jan 24; 58(1):98-102. PubMed ID: 15649677
    [Abstract] [Full Text] [Related]

  • 7. Underutilization of preventive strategies in patients receiving NSAIDs.
    Sturkenboom MC, Burke TA, Dieleman JP, Tangelder MJ, Lee F, Goldstein JL.
    Rheumatology (Oxford); 2003 Nov 24; 42 Suppl 3():iii23-31. PubMed ID: 14585915
    [Abstract] [Full Text] [Related]

  • 8. A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines.
    Price-Forbes AN, Callaghan R, Allen ME, Rowe IF.
    Rheumatology (Oxford); 2005 Jul 24; 44(7):921-4. PubMed ID: 15827035
    [Abstract] [Full Text] [Related]

  • 9. What happened to the prescribing of other COX-2 inhibitors, paracetamol and non-steroidal anti-inflammatory drugs when rofecoxib was withdrawn in Australia?
    Barozzi N, Tett SE.
    Pharmacoepidemiol Drug Saf; 2007 Nov 24; 16(11):1184-91. PubMed ID: 17636557
    [Abstract] [Full Text] [Related]

  • 10. Motivations and perceived influences on rural and urban general practitioners when prescribing conventional non-steroidal anti-inflammatory drugs or COX-2 inhibitors.
    Behan K, Cutts C, Tett SE.
    J Clin Pharm Ther; 2005 Aug 24; 30(4):337-43. PubMed ID: 15985047
    [Abstract] [Full Text] [Related]

  • 11. Changing perceptions and practices regarding aspirin, nonsteroidal anti-inflammatory drugs, and cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs among US primary care providers.
    Elnachef N, Scheiman JM, Fendrick AM, Howden CW, Chey WD.
    Aliment Pharmacol Ther; 2008 Nov 15; 28(10):1249-58. PubMed ID: 18729848
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Prevention and treatment of non-steroidal anti-inflammatory drug gastroenteropathy].
    Lanas A.
    Rev Gastroenterol Mex; 2004 Nov 15; 69(4):251-60. PubMed ID: 15765979
    [Abstract] [Full Text] [Related]

  • 14. Utilization of non-steroidal anti-inflammatory drugs in Quebec: adherence to the Canadian consensus on prescription guidelines.
    Moride Y, Ducruet T, Boivin JF, Lavoie F, Rochon S.
    Can J Clin Pharmacol; 2005 Nov 15; 12(2):e201-11. PubMed ID: 15998959
    [Abstract] [Full Text] [Related]

  • 15. Nonsteroidal antiinflammatory drug use among patients with GI bleeding.
    Dominick KL, Bosworth HB, Jeffreys AS, Grambow SC, Oddone EZ, Horner RD.
    Ann Pharmacother; 2004 Nov 15; 38(7-8):1159-64. PubMed ID: 15187205
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Inadequate prevention of NSAID-induced gastrointestinal events.
    Herings RM, Goettsch WG.
    Ann Pharmacother; 2004 May 15; 38(5):760-3. PubMed ID: 15031416
    [Abstract] [Full Text] [Related]

  • 18. An evidence-based approach to prescribing nonsteroidal antiinflammatory drugs. Third Canadian Consensus Conference.
    Tannenbaum H, Bombardier C, Davis P, Russell AS, Third Canadian Consensus Conference Group.
    J Rheumatol; 2006 Jan 15; 33(1):140-57. PubMed ID: 16331802
    [Abstract] [Full Text] [Related]

  • 19. The use of NSAIDs in rheumatic disorders 2005: a global perspective.
    Kean WF, Buchanan WW.
    Inflammopharmacology; 2005 Jan 15; 13(4):343-70. PubMed ID: 16354389
    [Abstract] [Full Text] [Related]

  • 20. Changes in physicians' practice of prescribing cyclooxygenase-2 inhibitor after market withdrawal of rofecoxib: a retrospective study of physician-patient pairs in Taiwan.
    Hsiao FY, Tsai YW, Huang WF.
    Clin Ther; 2009 Nov 15; 31(11):2618-27. PubMed ID: 20110006
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.